Loxapine (Adasuve) vs Olanzapine (Zyprexa Relprevv)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Loxapine (Adasuve)

Marketed by Lee's Pharmaceutical and partners

Phase 3 in Schizophreniasmall molecule
Reliable signal

NCT00628589 · Phase 3 · completed

The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).

Reported efficacy

Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)

Result source: NCT00628589

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointLoxapine (Adasuve)Olanzapine (Zyprexa Relprevv)
PANSS total, change—Not reported—Not posted · NCT00088491
CGI-S, change—Not reported-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
PANSS response—Not reported—Not posted · NCT00088491
PSP, change—Not reported—Not posted · NCT00088491
Relapse (% of patients)—Not reported20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489

PANSS total, change

Loxapine (Adasuve)
—Not reported
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

CGI-S, change

Loxapine (Adasuve)
—Not reported
Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489

PANSS response

Loxapine (Adasuve)
—Not reported
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

PSP, change

Loxapine (Adasuve)
—Not reported
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

Relapse (% of patients)

Loxapine (Adasuve)
—Not reported
Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Loxapine (Adasuve): 3 of 4 rows · Olanzapine (Zyprexa Relprevv): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLoxapine (Adasuve)Olanzapine (Zyprexa Relprevv)
Dropout rate
2.7%10 mga
NCT00628589 · Phase 3 · monotherapy
show 8 more results
1.7%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
54.9%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—10 mga
NCT00628589 · Phase 3 · monotherapy
show 8 more results
—5 mg
NCT00628589 · Phase 3 · monotherapy
—10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
9.8%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Serious AEs
0.9%10 mga
NCT00628589 · Phase 3 · monotherapy
show 8 more results
0%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
2.2%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
9.5%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
10 mga
dizziness 10.6% (placebo 9.6%)
dysgeusia 10.6% (placebo 2.6%)
sedation 10.6% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
show 8 more results
5 mg
sedation 12.9% (placebo 9.6%)
dysgeusia 8.6% (placebo 2.6%)
dizziness 5.2% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
10 mg
sedation 22% (placebo 14%)
dysgeusia 17.1% (placebo 9.3%)
headache 12.2% (placebo 2.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
5 mg
sedation 13.3% (placebo 14%)
dizziness 11.1% (placebo 9.3%)
dysgeusia 4.4% (placebo 9.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
10 mg
dizziness 75% (placebo 35.7%)
dysgeusia 75% (placebo 0%)
somnolence 75% (placebo 21.4%)
NCT00444028 · Phase 1 · registry result, not featured evidence
5 mg
dizziness 57.1% (placebo 35.7%)
fatigue 42.9% (placebo 7.1%)
dysgeusia 28.6% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
2.5 mg
dizziness 50% (placebo 35.7%)
nausea 50% (placebo 0%)
dysgeusia 33.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
1.25 mg
dizziness 25% (placebo 35.7%)
dysgeusia 25% (placebo 0%)
headache 25% (placebo 14.3%)
NCT00444028 · Phase 1 · registry result, not featured evidence
0.625 mg
dizziness 28.6% (placebo 35.7%)
disturbance in attention 14.3% (placebo 7.1%)
dysgeusia 14.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
a
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Loxapine (Adasuve)

PANSS-EC -8.6 vs -5.5 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00628589 · Phase 3 · monotherapy
show 1 more result
-8.1 vs -5.5 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
CGI-I 2.1 vs 2.8 placebo score @ 0.0119wk10 mg
absolute value · score
NCT00628589 · Phase 3 · monotherapy
show 1 more result
2.3 vs 2.8 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
CGI-I 67% (n=112) vs 35.7% (n=115) placebo @ 0.0119wk10 mg
responder rate · % of participants
NCT00628589 · Phase 3 · monotherapy · converted to % from 75 Participants as posted
show 3 more results
62.5% (n=40) vs 20.9% (n=43) placebo @ 0.0119wk*10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
56.9% (n=116) vs 35.7% (n=115) placebo @ 0.0119wk*5 mg
NCT00628589 · Phase 3 · monotherapy · converted to % from 66 Participants as posted
48.9% (n=45) vs 20.9% (n=43) placebo @ 0.0119wk*5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
PANSS-EC -8.56 vs -4.98 placebo PANSS units @ 0.0119wk10 mg
absolute change · PANSS units
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-6.71 vs -4.98 placebo PANSS units @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
BARS -2.02 vs -0.93 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.53 vs -0.93 placebo score @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
CGI-I 2.28 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk10 mg
absolute value · CGI-I Units (7=worse, 1=better)
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
2.53 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Olanzapine (Zyprexa Relprevv)'s landscape